secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K/A
Filed at:   2026-07-29T12:15:46+00:00
Accession:  0001140361-26-029964
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools signs definitive agreement to sell mass cytometry business to Multiplex Bio Inc.
--------------------------------------------------------------------------------

- Agreement dated July 28, 2026, for sale of mass cytometry business (CyTOF, Hyperion, Maxpar, Theia platforms) to Multiplex Bio Inc.
- Consideration includes Base Seller Note and Seller Working Capital Note; additional contingent consideration tied to Qualifying Exit.
- Sale subject to stockholder approval, regulatory clearances, and other customary conditions.
- Concurrently, Standard BioTools is pursuing acquisition of Treeline and potential sale of microfluidics business.
- Definitive agreement includes transition services, IP assignments, and other ancillary documents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126029964/0001140361-26-029964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000114036126029964/ef20078945_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-029964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer